



PATENT

ATTORNEY DOCKET NO. 50128/002003

Certificate of Mailing: Date of Deposit: June 7, 2002

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Kathy Meuse

Printed name of person mailing correspondence

Kathy Meuse

Signature of person mailing correspondence

TECH CENTER 1600/2900

JUN 19 2002

RECEIVED

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Michael Wolfe et al.

Art Unit: 1647

Serial No.: 10/003,674

Examiner:

Filed: - October 23, 2001

Customer No.: 21559

Title: SPECIFIC ANTAGONISTS FOR GLUCOSE-DEPENDENT  
INSULINOTROPIC POLYPEPTIDE (GIP)

Assistant Commissioner for Patents  
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the attached form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.


If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date:

June 7, 2002



Paul T. Clark  
Reg. No. 30,162

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE



Sheet 1 of 2

TECH CENTER 1600/2900

RECEIVED

JUN 19 2002

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50128/002003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No. 10/003,674
				Applicant M. Michael Wolfe et al.
				Filing Date October 23, 2001
				Group 1647
(37 C.F.R. §1.98(b))				IDS Filed June 7, 2002
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)				
	Cleator and Gourlay, "Release of Immunoreactive Gastric Inhibitory Polypeptide (IR-GIP) by Oral Ingestion of Food Substance," <i>Am. J. Surg.</i> 130:128-135, 1975.			
	Dupre et al., "Stimulation of Insulin Secretion by Gastric Inhibitory Polypeptide in Man," <i>J. Clin. Endocrinol. Metab.</i> 37:826-828, 1973.			
	Gremlich et al., "Cloning, Functional Expression, and Chromosomal Localization of the Human Pancreatic Islet Glucose-Dependent Insulinotropic Polypeptide Receptor," <i>Diabetes</i> 44:1202-1208, 1995.			
	Jornvall et al., "Amino Acid Sequence and Heterogeneity of Gastric Inhibitory Polypeptide (GIP)," <i>FEBS Letters</i> 123:205-210, 1981.			
	Kieffer et al., "Glucose-Dependent Insulinotropic Polypeptide Stimulated Insulin Release from a Tumor-Derived Beta-Cell Line (Beta TC3)," <i>Can. J. Physiol. Pharmacol.</i> 71:917-922, 1993.			
	Kolligs et al., "Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9-39) Amide," <i>Diabetes</i> 44:16-19, 1995.			
	Kreymann et al., "Glucagon-Like Peptide-1 7-36: A Physiological Incretin in Man," <i>Lancet</i> 2:1300-1304, 1987.			
	Mojsov et al., "Insulinotropin: Glucagon-Like Peptide I (7-37) Co-Encoded in the Glucagon Gene is a Potent Stimulator of Insulin Release in the Perfused Rat Pancreas," <i>J. Clin. Invest.</i> 79:616-619, 1987.			
	Nauck et al., "Additive Insulinotropic Effects of Exogenous Synthetic Human Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1-(7-36) Amide Infused at Near-Physiological Insulinotropic Hormone and Glucose Concentrations," <i>J. Clin. Endocrinol. Metab.</i> 76:912-917, 1993.			
	Nauck et al., "Insulinotropic Properties of Synthetic Human Gastric Inhibitory Polypeptide in Man: Interactions with Glucose, Phenylalanine, and Cholecystokinin-8," <i>J. Clin. Endocrinol. Metab.</i> 69:654-662, 1989.			
	Nauck et al., "Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses," <i>J. Clin. Endocrinol. Metab.</i> 63:492-498, 1986.			
	Nauck et al., "Reduced Incretin Effect in Type 2 (Non-Insulin-Dependent) Diabetes," <i>Diabetologia</i> 29:46-52, 1986.			
	Orskov et al., "Radio-Immunoassays for Glucagon-Like Peptides 1 and 2 (GLP-1 and GLP-2)," <i>Scand. J. Clin. Lab. Invest.</i> 47:165-174, 1987.			
	Orskov et al., "Proglucagon Products in Plasma of Noninsulin-Dependent Diabetics and Nondiabetic Controls in the Fasting State and After Oral Glucose and Intravenous Arginine," <i>J. Clin. Invest.</i> 87:415-423, 1991.			
	Rossowski et al., "Reduced Gastric Acid Inhibitory Effect of a pGIP(1-30) NH2 Fragment with Potent Pancreatic Amylase Inhibitory Activity," <i>Regul. Pept.</i> 29:9-17, 1992.			
	Salera et al., "Circadian Rhythm of Gastric Inhibitory Polypeptide (GIP) in Man," <i>Metabolism</i> 32:21-24, 1983.			
	Schmid et al., "Comparison of GLP-1(7-36amide) and GIP on Release of Somatostatin-Like Immunoreactivity and Insulin from the Isolated Rat Pancreas," <i>Z. Gastroenterol.</i> 28:280-284, 1990.			



RECEIVED

JUN 19 2002

Sheet 2

TECH CENTER 1600/2900

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50128/002003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No.	10/003,674
				Applicant	M. Michael Wolfe et al.
				Filing Date	October 23, 2001
				Group	1647
				IDS Filed	June 7, 2002
(37 C.F.R. §1.98(b))					
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
	Shima et al., "Effect of Glucagon-Like Peptide-1 on Insulin Secretion," <i>Regul. Pept.</i> 22:245-252, 1988.				
	Siegel et al., "Comparison of the Effect of GIP and GLP-1 (7-36amide) on Insulin Release from Rat Pancreatic Islets," <i>Eur. J. Clin. Invest.</i> 22:154-157, 1992.				
	Suzuki et al., "Reduced Insulinotropic Effects of Glucagonlike Peptide I-(7-36)-Amide and Gastric Inhibitory Polypeptide in Isolated Perfused Diabetic Rat Pancreas," <i>Diabetes</i> 39:1320-1325, 1990.				
	Takeda et al., "Sequence of an Intestinal cDNA Encoding Human Gastric Inhibitory Polypeptide Precursor," <i>Proc. Natl. Acad. Sci. USA</i> 84:7005-7008, 1987.				
	Tseng et al., "Chronic Desensitization of the Glucose-Dependent Insulinotropic Polypeptide Receptor in Diabetic Rats," <i>Am. J. Physiol.</i> 270:661-666, 1996.				
	Tseng et al., "Postprandial Stimulation of Insulin Release by Glucose-Dependent Insulinotropic Polypeptide (GIP). Effect of a Specific Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist in the Rat," <i>J. Clin. Invest.</i> 98:2440-2445, 1996.				
	Tseng et al., "Glucose-Dependent Insulinotropic Peptide: Structure of the Precursor and Tissue-Specific Expression in Rat," <i>Proc. Natl. Acad. Sci. USA</i> 90:1992-1996, 1993				
	Tseng et al., "Regulation of Glucose-Dependent Insulinotropic Peptide Gene Expression by a Glucose Meal," <i>Am. J. Physio.</i> 266:G887-G891, 1994.				
	Wang et al., "Glucagon-Like Peptide-1 is a Physiological Incretin in Rat," <i>J. Clin. Invest.</i> 95:417-421, 1995.				
	Wheeler et al., "Functional Expression of the Rat Pancreatic Islet Glucose-Dependant Insulinotropic Polypeptide Receptor: Ligand Binding and Intracellular Signaling Properties," <i>Endocrinology</i> 136:4629-4639, 1995.				
	Wolfe and Reel, "Inhibition of Gastrin Release by Gastric Inhibitory Peptide Mediated by Somatostatin," <i>Am. J. Physiol.</i> 250:G331-G335, 1986.				
	Wolfe et al., "Effects of Antibodies to Gastric Inhibitory Peptide on Gastric Acid Secretion and Gastrin Release in the Dog," <i>Gastroenterology</i> 84:941-948, 1983.				
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					